Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision Support
Healthcare organizations, compendia, and drug knowledgebase vendors use varying methods to evaluate and synthesize evidence on drug–drug interactions (DDIs). This situation has a negative effect on electronic prescribing and medication information systems that warn clinicians of potentially harmful medication combinations.
The aim of this study was to provide recommendations for systematic evaluation of evidence for DDIs from the scientific literature, drug product labeling, and regulatory documents.
A conference series was conducted to develop a structured process to improve the quality of DDI alerting systems. Three expert workgroups were assembled to address the goals of the conference. The Evidence Workgroup consisted of 18 individuals with expertise in pharmacology, drug information, biomedical informatics, and clinical decision support. Workgroup members met via webinar 12 times from January 2013 to February 2014. Two in-person meetings were conducted in May and September 2013 to reach consensus on recommendations.
We developed expert consensus answers to the following three key questions. (i) What is the best approach to evaluate DDI evidence? (ii) What evidence is required for a DDI to be applicable to an entire class of drugs? (iii) How should a structured evaluation process be vetted and validated?
Evidence-based decision support for DDIs requires consistent application of transparent and systematic methods to evaluate the evidence. Drug compendia and clinical decision support systems in which these recommendations are implemented should be able to provide higher-quality information about DDIs.
- 1.Aspden P, Institute of Medicine (U.S.). Committee on identifying and preventing medication errors. Preventing medication errors. Washington, DC: National Academies Press; 2007.Google Scholar
- 3.Centers for Disease Control and Prevention FASTSTATS—Emergency Department Visits. 2012. US Department of Health and Human Services. [cited 12/06/2013]; Available from: http://www.cdc.gov/nchs/fastats/ervisits.htm.
- 4.Centers for Disease Control and Prevention FASTSTATS—Hospital Utilization. 2010. US Department of Health and Human Services. [cited 12/06/2013]; Available from: http://www.cdc.gov/nchs/fastats/hospital.htm.
- 5.Centers for Medicare and Medicaid Services. Eligible Professional Meaningful Use Core Measures: Measure 2 of 15. 2010. US Department of Health and Human Services. [cited 01/09/2013]; Available from: http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/downloads/2_Drug_Interaction_ChecksEP.pdf.
- 16.Grizzle AJ, Mahmood MH, Ko Y, Murphy JE, Armstrong EP, Skrepnek GH, et al. Reasons provided by prescribers when overriding drug–drug interaction alerts. Am J Manag Care. 2007. p. 573–8 (United States).Google Scholar
- 22.Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc. 2001;41(2):161–5.Google Scholar
- 23.Ridgeley MS, Greenberg MD. Too many alerts, too much liability: sorting through the malpractice implications of drug–drug interaction clinical decision support. Saint Louis Univ J Health Law Policy. 2012;5(257):257–96.Google Scholar
- 24.Oates JA. Chapter 5. The science of drug therapy. In: Brunton LL, editor. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill, Medical Publishing Division; 2006.Google Scholar
- 27.Food and Drug Administration. Title 21–Food and Drugs Chapter I–Food and Drug Administration; US Department of Health and Human Services Subchapter D–Drugs for Human Use. 2013. [cited 7/28/14]; Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.33.
- 42.Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling recommendations: draft guidance. 2012. US Department of Health and Human Services. [cited 12/1/2014]; Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf.
- 43.Food and Drug Administration. Information for Healthcare Professionals on FDA’s New Prescribing Information for Drugs. US Department of Health and Human Services. [cited 10/29/10]; Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084189.htm.
- 44.Food and Drug Administration. Indexing structured product labeling for human prescription drug and biologic products. Docket No. FDA-2010-N-0256. Federal Register. 2010;2010(75):33312–3.Google Scholar
- 45.Horn JR, Hansten PD. Predicting the magnitude of drug interactions: the final frontier. Pharmacy Times. 2006;72.Google Scholar
- 47.Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811–9.CrossRefPubMedGoogle Scholar
- 50.Tamblyn R, Eguale T, Buckeridge DL, Huang A, Hanley J, Reidel K, et al. The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: a cluster randomized trial. J Am Med Inform Assoc. 2012;19(4):635–43.CrossRefPubMedCentralPubMedGoogle Scholar
- 56.Grade Working Group. [cited 7/28/14]; Available from: http://www.gradeworkinggroup.org/index.htm.
- 57.The University of Liverpool. HEP-Drug Interactions. [cited 12/1/14]; Available from: http://www.hep-druginteractions.org/.
- 58.The University of Liverpool. HIV-Drug Interactions. [cited 12/1/14]; Available from: http://www.hiv-druginteractions.org.
- 59.Horn JR, Hansten, Philip D. “Classy” drug interactions. Pharmacy Times. 2005. [cited 12/1/14]; Available at: http://www.pharmacytimes.com/publications/issue/2005/2005-06/2005-06-9585.